Adc Therapeutics SA Return on Equity

Adc Therapeutics SA (ADCT) currently reports a ROE of 42.47%. That is above the Healthcare sector average of 22.01%. Use the charts on this page to explore Adc Therapeutics SA's ROE history and peer comparisons.

Adc Therapeutics SA's ROE of 42.47% is higher than the Healthcare sector average of 22.01%. That is roughly 92.9% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Adc Therapeutics SA's current 42.47% should be judged against Healthcare norms (sector average: 22.01%) and against ADCT's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of 42.47%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 22.01%. From there, open related valuation or income-statement pages for Adc Therapeutics SA, and consider following ADCT for alerts when major investors trade the stock.

Adc Therapeutics SA is classified in the Healthcare sector. On ROE, it currently shows 42.47% versus a sector average near 22.01%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ADCT with unrelated industries.